NCT06951425View on ClinicalTrials.gov

An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Solid Tumors

Interventions

DRUG

TH-CART-027

3+3 dose escalation design: Dose Level 1: 0.3×10\^6 CAR+ T cells /kg; Dose Level 2: 1.0×10\^6 CAR+ T cells /kg; Dose Level 3: 3.0×10\^6 CAR+ T cells /kg

Trial Locations (1)

Unknown

Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai

All Listed Sponsors

collaborator

ThinkingBiomed

UNKNOWN

lead

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER